Display options
Cite
Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best Pract Res Clin Haematol. 2021;34(1):101257doi: 10.1016/j.beha.2021.101257.
Perl, A. E. (2021). Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best practice & research. Clinical haematology, 34(1), 101257. https://doi.org/10.1016/j.beha.2021.101257
Perl, Alexander E. "Which novel agents will have a clinically meaningful impact in AML at diagnosis?." Best practice & research. Clinical haematology vol. 34,1 (2021): 101257. doi: https://doi.org/10.1016/j.beha.2021.101257
Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis?. Best Pract Res Clin Haematol. 2021 Mar;34(1):101257. doi: 10.1016/j.beha.2021.101257. Epub 2021 Feb 13. PMID: 33762111.
Copy Download .nbib Format: NLM
Share it on

Best Pract Res Clin Haematol. 2021 Mar;34(1):101257. doi: 10.1016/j.beha.2021.101257. Epub 2021 Feb 13.

Which novel agents will have a clinically meaningful impact in AML at diagnosis?.

Best practice & research. Clinical haematology

Alexander E Perl

Affiliations

  1. Perelman School of Medicine at the University of Pennsylvania, Division of Hematology-Oncology, Abramson Cancer Center, Leukemia Program, Phiadelphia, PA, USA. Electronic address: [email protected].

PMID: 33762111 DOI: 10.1016/j.beha.2021.101257

Abstract

New drug approvals now afford AML physicians a wider choice of initial treatment options than ever before. Although chemotherapy for AML is by no means ready to be replaced entirely by novel agents, the role of traditional cytotoxics in AML therapy is rapidly changing. In particular, biologically targeted agents such as the BCL2 inhibitor venetoclax and inhibitors of FLT3 and IDH mutations stand out as drugs likely to take AML therapy in important new directions. Maximum response and survival benefits likely require combinations of novel agents and chemotherapy or multiple novel agents together. The recently-published phase 3 VIALE-A study demonstrates a very successful example of a new combination approach, which led to venetoclax plus azacitidine establishing itself as the new standard of care for patients unfit for intensive chemotherapy. One could reasonably expect other subsets of AML to benefit from this regimen or other applications of venetoclax combinations. Building on this experience, venetoclax-based regimens also have the potential to replace standard intensive cytarabine/anthracycline "7&3" induction approach for some if not many patients who are fit for induction. This review will describe novel agents with the greatest potential for impactful frontline applications that will change the AML treatment paradigm.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: Acute myeloid leukemia; BLC2 inhibition; FLT3 inhibition; IDH inhibition; Novel therapeutics

Publication Types